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Introduction
The use of newer "designer" hallucinogens is increasing, although the use of classic hallucinogens has waned (McCambridge et al., 2007) . Many compounds are freely available over the internet, and websites that promote their use share descriptions of the subjective effects of these drugs (e.g., www.erowid.org). Not all of these compounds have been specifically Very little is known about the effects of these three compounds. All are indolealkylamines and structurally similar to DMT (Table 1) . The most studied compound, 5-MeO-AMT, bound to 5-HT 1A and 5-HT 2 receptors (Glennon et al., 1990; Tomaszewski et al., 1992) . It also inhibited the reuptake and increased the release of monoamines in brain synaptosomes at micromolar concentrations . Similarly, 5-MeO-DET bound to 5-HT 2 receptors (Lyon et al., 1988) , and also inhibited reuptake but did not cause release of monoamines . 5-MeO-AMT lowered intraocular pressure (May et al., 2003) .
In rats trained to discriminate DOM (1 mg/kg, ip, 15 min) from saline, 5-MeO-AMT produced little effect at 15 min after administration, but racemate and both (+) and (1) isomers fully JPET #179705 substituted when tested 90 min after administration (Glennon et al., 1983b) . DIPT inhibited transport at SERT and also VMAT2 Cozzi et al., 2009 ).
The purpose of this study was to identify potential abuse liability of DIPT, 5-MeO-AMT, and 5-MeO-DET. First, locomotor activity was tested to determine the effective dose range and time course of behavioral effects. Second, the ability of these compounds to produce discriminative stimulus effects similar to those of known drugs of abuse was tested. Third, the ability of these compounds to bind to and activate molecular/pharmacological mechanisms used by known drugs of abuse was characterized.
As very little is known about the behavioral effects of these compounds, it was necessary to test for a range of potential discriminative stimulus effects. The effects of psychedelic compounds can be classified into 3 categories: hallucinogen, stimulant, and other (Glennon, 1999) . Further, the hallucinogens fall into three classes: simple tryptamines (indolealkylamines), ergolines, and phenethylamines (Nichols, 2004) . To test the effects of novel hallucinogens across all of these categories, different groups of rats were trained to discriminate each of the following compounds: DMT (indolealkylamine), LSD (ergoline), DOM (phenethylamine hallucinogen), methamphetamine (phenethylamine psychostimulant), MDMA (phenethylamine psychostimulant/hallucinogen), and cocaine (psychostimulant). Each of these compounds represents one of the classes of psychedelic compounds, and each one is also abused.
The training compounds used in this study not only come from different structural classes, but do not have completely overlapping discriminative stimulus effects (Gatch et al., This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on April 7, 2011 as DOI: 10.1124 at ASPET Journals on June 6, 2017 jpet.aspetjournals.org Downloaded from 2009; Winter, 2009) , thus affording a wide range of categories for testing abuse liability of the novel compounds. For example, MDMA is often not considered a hallucinogen in humans, even though it produces visual distortions and produces discriminative stimulus effects similar to both psychostimulants and hallucinogens (Gatch et al., 2009; Winter, 2009 ). These findings indicate that the discriminative stimulus effects may lie in between, or overlap the two classes, and that the MDMA discrimination may be useful for detecting weak discriminative stimulus effects of either type, or for detecting compounds with stimulus properties of both classes.
The third purpose of this study was to identify whether the test compounds act at receptors known to mediate the effects of drugs of abuse. Hallucinogens are typically thought to produce their sensory effects through activation of 5-HT 2A receptors, although there is also evidence for a contribution of 5-HT 1A receptors and perhaps other monoamine sites as well (Fiorella et al., 1995; Nichols, 2004; Nonaka et al., 2007) . In addition, tryptamine compounds, most notably serotonin, also act at the monoamine transporters (Adkins et al., 2001) . The ability of DIPT, 5-MeO-AMT, and 5-MeO-DET to bind to and/or activate 5-HT 1A and 2A receptors was tested, as well as their ability to bind to dopamine, norepinephrine, and serotonin transporters and to block uptake and/or promote release. Arachidonic acid release following activation of phospholipase A2 and inositol-monophosphate formation following activation of phospholipase C were used as measures of 5-HT2A receptor activation as LSD and other hallucinogens seem to preferentially activate this signal-transduction pathway (see review in Nichols, 2004) .
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Methods
Subjects
Male Sprague-Dawley rats were obtained from Harlan-Sprague Dawley (Indianapolis, IN). All rats were housed individually and were maintained on a 12:12 light/dark cycle (lights on at 7:00 AM). Body weights were maintained at 320-350 g by limiting food to 20 g/day which included the food received during operant sessions. Water was readily available. Male SwissWebster mice were obtained from Harlan (Indianapolis, IN) at approximately 8 weeks of age and tested at approximately 10 weeks of age. Mice were group housed in cages on a 12:12-h light/dark cycle and were allowed free access to food and water. All housing and procedures were in accordance with Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (National Research Council, 2003) and were approved by the University of North Texas Health Science Center Animal Care and Use Committee.
Discrimination Procedures
Standard operant chambers (Coulbourn Instruments, Allentown, PA) were connected to IBM-PC compatible computers via LVB interfaces (Med Associates, East Fairfield, VT). The computers were programmed in Med-PC for Windows, version IV (Med Associates, East Fairfield, VT) for the operation of the chambers and collection of data.
Using a two-lever choice methodology, separate groups comprised of 15 to 32 rats were trained to discriminate one of four compounds from saline: methamphetamine (1 mg/kg), MDMA (1.5 mg/kg), LSD (0.1 mg/kg), and DMT (5 mg/kg) as previously described (Gatch et This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on April 7, 2011 as DOI: 10.1124 at ASPET Journals on June 6, 2017 jpet.aspetjournals.org Downloaded from al., 2009). Rats received an injection of either saline or drug and were subsequently placed in the operant chambers, where food (45 mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses on a designated injection-appropriate lever. The pretreatment time was 10 min for methamphetamine and MDMA, 15 min for LSD, and 5 min for DMT. Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. The rats received approximately 60 of these sessions before they were used in tests for substitution of the experimental compounds. Rats were used in testing once they had achieved 9 of 10 sessions at 85% injection-appropriate responding for both the first reinforcer and total session. The training sessions occurred on separate days in a double alternating fashion (drug-drug-salinesaline-drug; etc.) until the training phase was complete, after which substitution tests of DIPT, 5-MeO-AMT, or 5-MeO-DET were introduced into the training schedule such that at least one saline and one drug session occurred between each test (drug-saline-test-saline-drug-test-drug; etc.). The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.
Test sessions lasted for a maximum of 20 min. In contrast with training sessions, both levers were active, such that 10 consecutive responses on either lever led to reinforcement. Data were collected until the first reinforcer was obtained, or for a maximum of 20 min. Each compound was tested in groups of six rats. Intraperitoneal injections (1 ml/kg) of saline, DIPT (0.5 -10 mg/kg), 5-MeO-AMT (0.1 -1 mg/kg), or 5-MeO-DET (0.05 -2.5 mg/kg) occurred 30 min prior to the start of the test session. A repeated measures design was used, such that each rat was tested at all doses of a given drug.
This article has not been copyedited and formatted. The final version may differ from this version. were developed and selected as described for other cell lines (Eshleman et al., 1999) . The cDNA for the 5-HT 1A receptor was purchased from Missouri S&T cDNA Resource Center (Rolla, MO).
The cells were grown to confluence in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% FetalClone (HyClone, Logan, Utah), 0.05% penicillin-streptomycin (pen-strep), and 300 µg/mL of G418. The cells were scraped from 150 mm plates into phosphate-buffered saline and centrifuged at 270 x g for 10 minutes. The cell pellet was homogenized in 50 mM Tris-HCl (pH 7.7) with a polytron, and centrifuged at 27,000 × g. The homogenization and This article has not been copyedited and formatted. The final version may differ from this version. (Newman-Tancredi et al., 1998) . GTPγS assay buffer (20 mM HEPES, pH 7.4, 10 mM MgCl 2 , 100 mM NaCl, and 0.2 mM dithiothreitol) was used throughout the assay. HEK-5-HT 1A cells were scraped from tissue culture plates into assay buffer, centrifuged at 515 x g for 15 min.
The supernatant was removed, and the pellet was homogenized in 10 ml buffer/ plate of cells.
The homogenate was centrifuged at 40,000 x g for 15 min, and the resulting pellet was washed 2 times by homogenization in 10 ml buffer and centrifugation to remove serotonin that was present in the growth medium. The final pellet from 4 plates was resuspended in 10 ml of assay buffer.
Cell membranes (40-75 μ g protein) were preincubated (10 min, room temperature) with test compound in duplicate in assay buffer. The reaction was initiated by the addition of GDP (3 This article has not been copyedited and formatted. The final version may differ from this version. compounds. Experiments were terminated by rapid filtration over Filtermat A with ice-cold saline using a Tomtec cell harvester and radioactivity determined by liquid scintillation counting.
[
I]DOI binding
Binding to 5-HT 2A receptors was tested in human embryonic kidney cells expressing the human 5-HT 2A receptor (HEK-h5HT 2A ) adapting methods described earlier (Knight et al., 2004) .
The cDNA for the h5HT 2A receptor was purchased from Missouri S&T cDNA Resource Center.
The cells were grown until confluent on 15 cm plates. Medium was removed, cells were washed with phosphate-buffered saline, scraped into 2 ml phosphate-buffered saline and frozen at -20 o C until needed. Cell suspension was thawed, 10 ml assay buffer (50 mM Tris, pH 7.4 at 37 o C, with 0.1% ascorbic acid and 5 mM CaCl 2 ) was added per plate of cells, and polytronned at setting 6 for 5 sec. The homogenate was centrifuged at 30,000 x g for 20 min. To minimize the residual serotonin concentration, the pellet was resuspended in buffer, polytronned, and centrifuged as above. The final pellet was resuspended in 2 ml buffer/plate of cells.
The binding assay included test compound, serotonin or buffer, cell homogenate, placed on ice and medium was transferred from each well to a microfuge tube. To pelletize any cells that may have become detached during the assay, the medium was centrifuged at 13,000 rpm for 1 min. Aliquots of media (400 μ l) were transferred to scintillation vials and counted on a Beckman L4801 liquid scintillation counter. Ketanserin (30 µM) was used to define nonspecific release.
Inositol-1-phosphate (IP-1) accumulation
Activation of 5-HT 2A receptors was tested by measuring the accumulation of inositol monophosphate using the IP-1 Elisa kit (Cisbio, Bedford, MA). Cells were plated at a density of This article has not been copyedited and formatted. The final version may differ from this version. μ l aliquots of the lysates were added to the IP-1 plate.
The assay was conducted according to kit instructions. Stimulated IP-1 formation was normalized to the maximal effect of serotonin, which was determined in each assay.
hDAT, hSERT or hNET Binding, Uptake, and Release
The methods for characterizing the effects of the monoamine transporters have previously been described in detail (Eshleman et al., 1999 with the last 6 min (3 fractions) collected. Drug was added, and 24 min (12 fractions) of effluent were collected. SDS (1%) was then perfused, and 4 fractions, 2.5 min each, were collected.
Positive controls were methamphetamine (hDAT and hNET) and p-chloroamphetamine, (hSERT). Radioactivity in the samples was determined using conventional liquid scintillation spectrometry. Fractional release was the amount of radioactivity in a fraction divided by the total radioactivity remaining in the sample. 
Data Analysis
Drug discrimination data are expressed as the mean percentage of drug-appropriate responses occurring in each test period. Rates of responding were expressed as a function of the number of responses made divided by the total session time. Graphs for percent drug-appropriate responding and response rate were plotted as a function of dose of test compound (log scale).
Percent drug-appropriate responding was shown only if at least 3 rats completed the first fixed ratio. Full substitution was defined as >80% drug-appropriate responding and not statistically different from the training drug.
The potencies of DIPT, 5-MeO-AMT, and 5-MeO-DET were calculated by fitting straight lines to the dose-response data for each compound by means of TableCurve 2D (Jandel Scientific, San Rafael, CA). Straight lines were fitted to the linear portion of dose-effect curves,
including not more than one dose producing <20% of the maximal effect and not more than one dose producing >80% of the maximal effect. Other doses were excluded from the analyses. Rates of responding were expressed as a function of the number of responses made divided by the total session time. Response rate data was analyzed by one-way repeated measures analysis of variance. Effects of individual doses were compared to the vehicle control value using a priori contrasts. The criterion for significance was set a priori at p<0.05.
This article has not been copyedited and formatted. The final version may differ from this version. For release assays, area under the curve (AUC) was calculated using GraphPad Prism, and EC 50 values were determined using nonlinear regression. One-way ANOVAs were conducted using the log values of the K i , IC 50 , or EC 50 values followed by Tukey's post hoc analysis.
This article has not been copyedited and formatted. The final version may differ from this version. . Higher doses were not tested due to convulsions at 25 mg/kg (2/2 rats).
Within the dose range of 2.5 to 10 mg/kg, DIPT failed to substitute for the discriminative stimulus effects produced by 10 mg/kg of cocaine, 1 mg/kg of (+)-methamphetamine, or 1.5 mg/kg of MDMA (Fig. 1) . DIPT produced a maximum of 38% cocaine-appropriate responding, and less than 20% drug-appropriate responding in the methamphetamine-and MDMA-trained rats. A nearly complete suppression of response rates was observed following 10 mg/kg DIPT in (Table 2 ). The rank order of potency (EC 50 ) was 5-MeO-DET = 5-MeO-AMT (p>0.05) > DIPT (p<0.05). All three compounds were less potent than the endogenous ligand serotonin (p<0.001), and the standard compound dihydroergotamine (p<0.001). 5-MeO-DET and 5-MeO-AMT had equal efficacy as compared to serotonin, however, DIPT produced only 58% of the maximal effect of serotonin.
5-HT 2A Receptors
DIPT, 5-MeO-DET, and 5-MeO-AMT all bound to 5-HT 2A receptors in HEK cells at nanomolar concentrations (Table 2 ). The rank order of affinity (K i value) was 5-MeO-AMT > 5-MeO-DET (p<0.01) > DIPT (p<0.05). 5-MeO-DET and DIPT had lower affinity than the endogenous ligand serotonin (p<0.001) and all three test compounds had lower affinity than the standard compound LSD (p<0.001). The Hill coefficients were different from one. All three test compounds were agonists in the functional assay for 5-HT 2A receptors, release of arachidonic acid ( Table 2) and DIPT were less potent than serotonin (p<0.05) and LSD (p<0.001). However, the efficacy of the three test compounds at release of arachidonic acid was the same as for the standard, LSD.
Consistent with these results, all three compounds were agonists in the 5-HT 2A IP-1 functional assay ( Table 2 ). The rank order of potency was 5-MeO-AMT>5-MeO-DET (p<0.01)=DIPT (p>0.05). 5-MeO-AMT was more potent than serotonin (p<0.05) and less potent than LSD (p<0.05), while DIPT and DET were less potent than LSD (p<0.001) but had similar potency to serotonin (p>0.05). The efficacies of the three test compounds were similar to those of serotonin and LSD (p>0.05).
Biogenic Amine Transporters
5-MeO-AMT, 5-MeO-DET, DIPT produced little or no interaction with dopamine and norepinephrine transporters at concentrations less than 10 μ M (Table 3) . None of the three test compounds had measureable affinity for the dopamine and norepinephrine transporters.
However, 5-MeO-AMT blocked dopamine uptake with an IC 50 in the low micromolar range (2.69 μ M). None of the three test compounds elicited release of dopamine or norepinephrine.
In contrast, DIPT, 5-MeO-DET, and 5-MeO-AMT all produced measurable effects at the serotonin transporter at nanomolar or low micromolar concentrations (Table 3) DIPT had similar potency (p>0.05) and 5-MeO-DET and 5-MeO-AMT had lower potency (p<0.001). Only 5-MeO-AMT elicited serotonin release. 5-MeO-AMT was approximately equipotent to p-chloroamphetamine at serotonin release (unpaired 2-tailed t-test, p>0.05), but was less efficacious, producing only 37% of the maximal effect of p-chloroamphetamine (Table   3 ).
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Discussion
The discriminative stimulus effects of DIPT, 5-MeO-DET, and 5-MeO-AMT were tested in separate groups of rats trained to discriminate LSD, DOM, DMT, MDMA, methamphetamine, or cocaine from saline. In addition, the effects of DIPT, 5-MeO-DET, and 5-MeO-AMT on locomotor activity were tested. Finally, the ability of DIPT, 5-MeO-DET, and 5-MeO-AMT to bind and activate 5-HT 1A and 5-HT 2A receptors or serotonin, dopamine, and norepinephrine transporters was tested. The receptor mechanisms and behavioral effects of DIPT, 5-MeO-DET, and to a lesser extent, 5-MeO-AMT were similar to those of abused hallucinogens such as LSD, DOM, and DMT, but not to those of the psychostimulants, such as methamphetamine and cocaine.
DIPT showed the most overlap with the discriminative stimuli produced by hallucinogens: full substitution for DOM and DMT, and relatively high levels of LSDappropriate responding (68%). DIPT produced little or no drug-appropriate responding in the rats trained to discriminate methamphetamine, MDMA, and cocaine. The highest dose of DIPT tested (25 mg/kg) produced convulsions in both of the two rats tested. In terms of its mechanism of action, DIPT was most potent at binding to the serotonin transporter and blocking serotonin uptake, but also bound to and activated 5-HT 2A receptors with full efficacy at nanomolar concentrations in both functional assays. DIPT was less efficacious at activating 5-HT 1A
receptors, but 5-HT 1A activity is not thought to be necessary for hallucinogenic effects (Nichols, 2004) . These findings are similar to earlier reports that DIPT blocked serotonin uptake Cozzi et al., 2009) . One study also reported that DIPT blocked uptake of dopamine and This article has not been copyedited and formatted. The final version may differ from this version.
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norepinephrine, but at micromolar concentrations, which were higher than those tested in the present study . Because DIPT shared discriminative stimulus effects and mechanism of action with the currently abused hallucinogens DOM, DMT, and LSD, DIPT may also have substantial potential for abuse, which agrees with the large number of reports of human use on the internet (e.g., at www.Erowid.org). Further, the incidence of convulsions indicates that DIPT has dangerous effects at high doses.
5-MeO-DET fully substituted for the discriminative stimulus effects of DMT, a component of the shamanistic entheogen ayahuasca, which has recently attracted large increases in use (Halpern, 2004; McKenna, 2004; Gable, 2007) . 5-MeO-DET also produced relatively high levels of MDMA-appropriate responding (59%), but produced little drug-appropriate responding in rats trained to discriminate LSD, DOM, cocaine, or methamphetamine. 5-MeO-DET had highest affinity for the 5-HT 1A receptors, having 10-fold and 150-fold higher affinity at 5-HT 1A than at 5-HT 2A receptors and the serotonin transporter, respectively. 5-MeO-DET was fully efficacious at 5-HT 1A and 5-HT 2A receptors. These findings are in agreement with the observation that 5-MeO-DET binds to 5-HT 2 receptors (Lyon et al., 1988) 5-MeO-AMT produced a maximum of 67% LSD-appropriate responding. In DMTtrained rats, 5-MeO-AMT produced an inverted u-shaped function, such that the 0.5 mg/kg dose elicited DMT-appropriate responding (43%), but a higher dose produced markedly lower levels of DMT-appropriate responding (9%) as well as substantial suppression of responding. The rats that were most sensitive to the stimulus effects of 5-MeO-AMT and chose the DMT-appropriate lever were also the most sensitive to rate suppression. This suggests that there may a subpopulation of rats in which low doses of 5-MeO-AMT produce discriminative stimulus effects similar to DMT, and another sub-population in which they do not. In the DOM-, MDMA-, methamphetamine-, and cocaine-trained rats, 5-MeO-AMT produced only small amounts of drug-appropriate responding, but suppression of response rate prevented testing higher doses. It is a limitation of the drug discrimination assay that the discriminability of a drug cannot be assessed if the subjects do not press the levers. Because 5-MeO-AMT suppressed responding, we cannot tell if those or higher doses would produce greater amounts of substitution. It should be noted that an earlier report using rats trained to discriminate DOM from saline also reported little or no substitution by 5-Meo-AMT at 15 min, but saw full substitution for DOM at 90 min (Glennon et al., 1983a) . Longer pretreatment times were not tested in the present study as the locomotor activity data showed the largest decrease in activity at 10-20 min and no effects at 90 min. These findings suggest that the time course of locomotor activity may not always predict the time course of the discriminative stimulus effects of hallucinogens, nor do locomotor effects predict discrimination performance, as DIPT decreased locomotor activity, whereas 5-MeO-DET increased locomotor activity, but both substituted for at least one compound. Nevertheless, the locomotor effects were good predictors of the potency of the compounds in the discrimination tests and for suppression of response rate. receptors (Glennon et al., 1990; Tomaszewski et al., 1992) . 5-MeO-AMT was actually more efficacious at activation of 5-HT 1A receptors than was DIPT in the present study even though DIPT had stronger stimulus effects than 5-MeO-AMT. This finding suggests that 5-HT 1A receptors may not be a major contributor to the discriminative stimulus effects of hallucinogens, or at least those of DIPT. There is a substantial number of reports of recreational use of 5-MeO-AMT, which is known by the street name Alpha-O (e.g., www.erowid.org). Large doses have been reported to lead to long "trips" and reports of unpleasant subjective effects, vomiting, seizures, and possibly lethality. The rats in the present study may have been more sensitive to these adverse effects than to the hallucinogen-like stimulus effects, leading to the rate suppression and lack of substitution.
Psychedelic compounds have various chemical structures, so it is important to test the effects of novel compounds across a range of categories. Although activation of 5-HT 2A receptors is thought to be a primary mechanism of action for hallucinogens, the precise mechanism is not known (Nichols, 2004; Winter 2009) . It was also possible that these compounds have other mechanisms of action that could contribute to abuse liability, so a variety of molecular mechanisms were tested. Not surprisingly, these three tryptamines produced behavioral effects most similar to those of DMT, which is structurally similar. Overall, each of the compounds produced a different profile of substitution for the discriminative stimulus effects of several psychoactive compounds and a different profile of molecular mechanism. Testing a This article has not been copyedited and formatted. The final version may differ from this version. It should be noted that different species were used in the different assays. Mice were used in the locomotor activity studies, rats in the discrimination studies, and human cell lines in the binding and functional assays. The mouse data accurately predicts the behaviorally active dose range in the rat and is fairly good at predicting time course. Human cell lines were chosen as they are more directly relevant to human brain mechanisms and behavior. In addition, inference about abuse liability was made based upon stimulus similarity to known drugs of abuse and upon mechanisms of action similar to those of known drugs of abuse. Other classic methods of abuse liability testing include self-administration, and testing for development of dependence and withdrawal. Unfortunately, these assays are of limited use with hallucinogens as these compounds are typically not self-administered in non-human animals, and do not produce dependence (Deneau et al., 1969; Nichols, 2004; Fantegrossi et al., 2008 ).
In conclusion, DIPT and 5-MeO-DET shared stimulus effects with various abused hallucinogens, and so may have similar abuse liability. In addition, both compounds showed serious adverse effects such as tremors/convulsions, or lethality. In contrast, 5-MeO-AMT showed only low levels of drug-appropriate responding for the various abused hallucinogens at the doses and time tested. However, the large rate suppressant effects may have prevented detection of hallucinogen-like discriminative effects. These studies provide evidence for increased control of DIPT and 5-MeO-DET, but further testing of 5-MeO-AMT will be necessary to confirm its abuse liability.
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